Argenica Therapeutics (ASX:AGN) said the the final patient in its phase two clinical trial of ARG-007 in acute ischaemic stroke has been dosed, according to a Friday Australian bourse filing.
The phase two trial dosed a total of 92 patients with confirmed large vessel occlusion strokes and who underwent an endovascular thrombectomy procedure to remove the clot.
Half of these patients received an intravenous infusion of a saline placebo, and half received an intravenous infusion of ARG-007. The trial will remain blinded until the final patient dosed has their follow-up functional assessment performed at 90 days post-stroke.
Top-line data are expected to be released in the third quarter. The trial is seeking to evaluate the safety of the ARG-007 drug candidate and characterize the effect of the candidate on reducing infarct volume in participants with acute ischaemic stroke.
Argenica Therapeutics' shares rose almost 3% in recent trading on Friday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.